B+
Bull case
25%
Probability
Target price
$210.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
DVA
DaVitaBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The Q2 print supports a constructive operating case: EPS was $4.02, operating margin improved sequentially, free cash flow remained strong, and repurchases continued. Sustained reimbursement, volume, and cost execution could support a recovery toward the packet's $230 median target.
Posture
Constructive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-29 · AMC.
What can break
Current analyst revisions and a robust public peer valuation set are unavailable; only Fresenius Medical Care is a clear direct public operating peer.
Momentum
42
Value
69
Sentiment
50
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $192.00 · Bull $210.00 · Bear $160.00Analysis 2026-08-07; returns require an exact persisted reference.
Earnings
2026-10-29 · AMC
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-07 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $229.00
Why
Momentum42 · Δ7d -9.4
Value69 · Δ7d +0.1
Sentiment50 · Δ7d +3.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-29 · AMC.
- • Value remains the lead driver in the composite, 7D delta +0.1.
Contradictions & invalidation
- • Current analyst revisions and a robust public peer valuation set are unavailable; only Fresenius Medical Care is a clear direct public operating peer.
- • Normalized non-acquired treatment growth remains low, limiting organic volume visibility.
- • The market response was not clearly supportive, normalized non-acquired treatment growth remained only 0.3% year over year, revenue per treatment declined sequentially, and the company added $500 million of term debt.
Catalyst clock
2026-10-29 · AMC
Q2 results showed stronger margins and cash generation, but mature underlying volume
Lead driver: Value · See fundamentals
Momentum
42
8% active weight
Current posture
7d trendFlat
Δ7d
-9.4
Δ21d
+2.0
Value
69
47% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.3
Sentiment
50
45% active weight
Current posture
7d trendFlat
Δ7d
+3.2
Δ21d
-13.0
Why this grade
Composite grade B. Momentum 42.2 / Value 68.9 / Sentiment 49.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-07. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$192.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$160.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$11.72B
Beta
0.99
Shares Out
63.8M
P/E (TTM)
11.7
P/S (TTM)
0.60
P/FCF (TTM)
6.22
Rev YoY
+5.2%
EPS YoY
+55.8%
Gross Margin
+27.3%
Op Margin
+14.9%
Net Debt
$12.29B
Current Ratio
1.47
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data